{
    "clinical_study": {
        "@rank": "97453", 
        "arm_group": [
            {
                "arm_group_label": "Sequence 1 fasted", 
                "arm_group_type": "Experimental", 
                "description": "Day 1: Lesinurad 400 mg once daily (qd)\nDay 5: Ranitidine 150 mg twice daily (bid)\nDay 6: Lesinurad 400 mg (qd) + ranitidine 150 mg (bid). Ranitidine dosed at -2 hours predose and 12 hours postdose of lesinurad.\nDay 7: Ranitidine 150 mg (bid)"
            }, 
            {
                "arm_group_label": "Sequence 2 fasted", 
                "arm_group_type": "Experimental", 
                "description": "Day 1: Ranitidine 150 mg (bid)\nDay 2: Lesinurad 400 mg (qd) + ranitidine 150 mg (bid). Ranitidine dosed at -2 hours predose and 12 hours postdose of lesinurad\nDay 3: Ranitidine 150 mg (bid)\nDay 7: Lesinurad 400 mg (qd)"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a drug-drug interaction study in healthy volunteers to evaluate the potential\n      pharmacokinetic (PK) effects of ranitidine on lesinurad."
        }, 
        "brief_title": "Lesinurad Interaction Study With Ranitidine", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "This study will evaluate the potential effect of ranitidine on the pharmacokinetics of\n      lesinurad. An earlier study demonstrated an effect on lesinurad PK in the presence of both\n      calcium-containing and magnesium- and aluminum-containing antacids. The current study will\n      assess whether raising gastric pH, without the presence of these cations, affects lesinurad\n      PK and PD under the fasted state. If an impact is seen, then the optional second cohort will\n      be conducted under the fed state."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  body weight \u2265 50 kg (110 lbs) and body mass index \u2265 18 and \u2264 30 kg/m2.\n\n          -  Screening sUA value \u2264 7.0 mg/dL.\n\n          -  free of any clinically significant disease that requires a physician's care and/or\n             would interfere with study evaluations or procedures.\n\n          -  Subject has no clinically relevant abnormalties in vital signs, ECG, physical\n             examination or safety laboratory values per the Investigator's judgment.\n\n        Exclusion Criteria:\n\n          -  history or clinical manifestations of significant metabolic, hematological,\n             pulmonary, cardiovascular, gastrointestinal, neurologic, hepatic renal,urological, or\n             psychiatric disorders.\n\n          -  history or suspicion of kidney stones.\n\n          -  undergone major surgery within 3 months prior to Day 1.\n\n          -  donated blood or experienced significant blood loss (> 450 mL) within 12 weeks prior\n             to Day 1 or gave a plasma donation within 4 weeks prior to the Screening visit.\n\n          -  inadequate venous access or unsuitable veins for repeated venipuncture."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01908257", 
            "org_study_id": "RDEA594-127"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Sequence 1 fasted", 
                    "Sequence 2 fasted"
                ], 
                "intervention_name": "lesinurad 400 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Sequence 1 fasted", 
                    "Sequence 2 fasted"
                ], 
                "intervention_name": "ranitidine 150 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Sequence 1 fasted", 
                    "Sequence 2 fasted"
                ], 
                "intervention_name": "lesinurad 400 mg + ranitidine 150 mg", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Ranitidine", 
                "Ranitidine bismuth citrate"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "January 8, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Cypress", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "90630"
                }
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1, Open-Label, Drug-Drug Interaction Study to Evaluate the Potential Effects of Ranitidine on the Pharmacokinetics of Lesinurad in Healthy Adult Male Subjects", 
        "overall_official": {
            "affiliation": "Ardea Biosciences, Inc.", 
            "last_name": "S. Bradley, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Profile in terms of Cmax, Tmax, AUC, CL/F, t1/2\nCmax: maximum concentration; Tmax: time to reach max plasma concentration; AUC: area under the concentration-time curve; CL/F: total body clearance corrected for bioavailability; t1/2: apparent terminal half-life", 
            "measure": "PK profile of lesinurad from plasma and urine", 
            "safety_issue": "No", 
            "time_frame": "Days 1 and 6 (Sequence 1) or Days 2 and 7 (Sequence 2)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01908257"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Incidence of Adverse Events and Changes in Laboratory, Electrocardiogram, and Vital Signs Parameters", 
                "safety_issue": "Yes", 
                "time_frame": "6 weeks"
            }, 
            {
                "description": "Profile in terms of serum urate concentration", 
                "measure": "PD profile of lesinurad from serum", 
                "safety_issue": "No", 
                "time_frame": "Days 1 and 6 (Sequence 1) or Days 2 and 7 (Sequence 2)"
            }
        ], 
        "source": "Ardea Biosciences, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ardea Biosciences, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}